Vivoryon Therapeutics NV (VVY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has a cash flow conversion efficiency ratio of -0.838x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.96 Million ≈ $-4.63 Million USD) by net assets (€4.73 Million ≈ $5.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View today's stock price for Vivoryon Therapeutics NV for real-time trading data and today's change.
Vivoryon Therapeutics NV - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Vivoryon Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Vivoryon Therapeutics NV (VVY) market capitalisation for the company's overall valuation and market capitalisation.
Vivoryon Therapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivoryon Therapeutics NV ranked by their cash flow conversion efficiency. Also see Vivoryon Therapeutics NV total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
0.188x |
|
Widodo Makmur Unggas Tbk PT
JK:WMUU
|
-0.001x |
|
Batavia Prosperindo Finance
JK:BPFI
|
-0.123x |
|
Industrial Investment Trust Limited
NSE:IITL
|
0.155x |
|
Vintcom Technology PCL
BK:VCOM
|
0.083x |
|
Alpha Exploration Ltd
V:ALEX
|
-0.010x |
|
Aurumin Ltd
AU:AUN
|
0.017x |
|
Toplus Global Co Ltd
TWO:3522
|
0.087x |
Annual Cash Flow Conversion Efficiency for Vivoryon Therapeutics NV (2011–2025)
The table below shows the annual cash flow conversion efficiency of Vivoryon Therapeutics NV from 2011 to 2025. Review Vivoryon Therapeutics NV financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.73 Million ≈ $5.53 Million |
€-8.46 Million ≈ $-9.88 Million |
-1.789x | +26.49% |
| 2024-12-31 | €7.88 Million ≈ $9.21 Million |
€-19.17 Million ≈ $-22.42 Million |
-2.433x | -196.88% |
| 2023-12-31 | €26.28 Million ≈ $30.73 Million |
€-21.54 Million ≈ $-25.18 Million |
-0.820x | +0.32% |
| 2022-12-31 | €26.51 Million ≈ $30.99 Million |
€-21.79 Million ≈ $-25.48 Million |
-0.822x | -20.93% |
| 2021-12-31 | €16.56 Million ≈ $19.36 Million |
€-11.26 Million ≈ $-13.16 Million |
-0.680x | -27.23% |
| 2020-12-31 | €26.22 Million ≈ $30.66 Million |
€-14.01 Million ≈ $-16.38 Million |
-0.534x | -96.41% |
| 2019-12-31 | €42.66 Million ≈ $49.88 Million |
€-11.61 Million ≈ $-13.57 Million |
-0.272x | +95.22% |
| 2018-12-31 | €1.23K ≈ $1.44K |
€-6.99K ≈ $-8.18K |
-5.686x | -318.73% |
| 2017-12-31 | €8.92K ≈ $10.43K |
€-12.12K ≈ $-14.17K |
-1.358x | -67.77% |
| 2016-12-31 | €16.38K ≈ $19.15K |
€-13.26K ≈ $-15.50K |
-0.809x | -7.50% |
| 2015-12-31 | €16.13K ≈ $18.86K |
€-12.15K ≈ $-14.20K |
-0.753x | -13.56% |
| 2014-12-31 | €15.97K ≈ $18.67K |
€-10.59K ≈ $-12.38K |
-0.663x | -132.85% |
| 2013-12-31 | €-4.22 Million ≈ $-4.94 Million |
€-8.53 Million ≈ $-9.97 Million |
2.018x | +189.94% |
| 2012-12-31 | €5.37 Million ≈ $6.27 Million |
€-12.04 Million ≈ $-14.08 Million |
-2.244x | -134.20% |
| 2011-12-31 | €14.95 Million ≈ $17.47 Million |
€-14.32 Million ≈ $-16.74 Million |
-0.958x | -- |
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more